Arbutus Biopharma (ABUS) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to -$0.04.
- Arbutus Biopharma's EPS (Weighted Average and Diluted) rose 6000.0% to -$0.04 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.23, marking a year-over-year increase of 4651.16%. This contributed to the annual value of -$0.38 for FY2024, which is 1438.5% up from last year.
- According to the latest figures from Q3 2025, Arbutus Biopharma's EPS (Weighted Average and Diluted) is -$0.04, which was up 6000.0% from $0.01 recorded in Q2 2025.
- Arbutus Biopharma's EPS (Weighted Average and Diluted)'s 5-year high stood at $0.01 during Q2 2025, with a 5-year trough of -$0.24 in Q3 2021.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.11 (2022), whereas its average is -$0.12.
- Within the past 5 years, the most significant YoY rise in Arbutus Biopharma's EPS (Weighted Average and Diluted) was 10909.09% (2025), while the steepest drop was 3000.0% (2025).
- Quarter analysis of 5 years shows Arbutus Biopharma's EPS (Weighted Average and Diluted) stood at -$0.15 in 2021, then rose by 6.67% to -$0.14 in 2022, then increased by 14.29% to -$0.12 in 2023, then surged by 43.88% to -$0.07 in 2024, then soared by 40.6% to -$0.04 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.04 in Q3 2025, compared to $0.01 in Q2 2025 and -$0.13 in Q1 2025.